News | Heart Failure | December 29, 2015

BioVentrix Announces 30th Clinical Case for Revivent-TC Heart Failure Intervention

Less invasive procedure reduces size of left ventricle

BioVentrix, Revivent-TC Ventricular Enhancement System, interventional heart failure

BioVentrix closed-chest Revivent-TC Ventricular Enhancement System reduces the size of the ventricle for more efficient pumping in heart failure patients.

December 29, 2015 — BioVentrix in mid-December announced the successful completion of the 30th clinical case using the closed-chest Revivent-TC Ventricular Enhancement System for heart failure (HF). The hybrid procedure was performed by Prof. Petr Neuzil (interventional cardiologist) and Dr. Ivo Skalsky (cardiothoracic surgeon) on a 38-year-old female patient at the Na Holmoce Hospital in Prague, Czech Republic.   

The Less Invasive Ventricular Enhancement or the LIVE procedure, utilizing this new TransCatheter approach, is in clinical trials throughout Europe.  This case comes on the heels of other successful Revivent-TC cases performed recently in Spain, Italy, France, and Germany. 
   
"Before the LIVE procedure, this patient's quality of life was severely impacted by her heart failure to the point where she could no longer walk even short distances without discomfort.  The Revivent-TC system allows treatment of patients with worsening heart failure and those that are already very ill without opening the chest," said Neuzil.  

"The adoption of the Revivent-TC system allows us to treat the underlying cause of heart failure by reshaping the left ventricle to improve pumping efficiency and reduce wall stress," Skalsky added.

Recent analysis has shown that 76 percent of patients with mitral regurgitation that were treated with the Revivent technology had an added benefit of improvement in mitral valve functionality.  

BioVentrix has reported an average reduction of 31 percent in Left Ventricular volume and a 14 percent improvement ejection fraction (EF) at one-year post-op follow-up. The data continues to show the same volume reduction and ejection fraction increase with this hybrid approach as was demonstrated with the previous surgical technique.

Placement of the Revivent-TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a closed-chest, TransCatheter approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion.

For more information: http://bioventrix.com

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init